Company: CERO
Filing Date: 2025-02-05
Form Type: S-1/A
Source: 0001213900-25-010230
Chunk: 342

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-02-05
Form: S-1/A
Chunk 342
---
| Cash                           |     | $            | 96,873 |     | $ |    475,870 |
| Restricted cash                |     |              |      — |     |   | 41,665,974 |
| Total cash and restricted cash |     | $            | 96,873 |     | $ | 42,141,844 |

Money Market Funds Held in Trust Account

At December 31, 2023, the
assets held in Trust Account were held in money market funds that invested in U.S. Treasury securities. At December 31, 2022, substantially
all of the assets held in the Trust Account were held as cash. The Company’s investments held in the Trust Account are classified
as trading securities. Trading securities are presented on the balance sheets at fair value at the end of each reporting period. Gains
and losses resulting from the change in fair value of investments held in the Trust Account and interest earned on marketable securities
are included in the accompanying statements of operations. The estimated fair values of investments held in the Trust Account are
determined using available market information.

Shareholder Redemption Liability

On December 20, 2022,
in connection with the Company’s special meeting held to consider the First Charter Amendment, the Company’s stockholders
redeemed shares of Class A common stock subject to possible redemption at $ per share redemption value,
plus a pro rata share of interest earned. Of the total amount redeemed, payments for shares of Class A common
stock totaling $ plus a true-up payment of $ for a total liability of $ were subsequently paid to redeeming
stockholders on January 3, 2023. Therefore, a portion of the total redemption payment has been classified as a stockholder redemption
liability in the accompanying balance sheet as of December 31, 2022.

Offering Costs Associated with the IPO

Offering costs, including
additional underwriting fees associated with the underwriter’s partial exercise of the over-allotment option, consist principally
of legal, accounting, underwriting fees and other costs directly related to the IPO. Offering costs, including those attributable to the
underwriter’s partial exercise of the over-allotment option, amounted to $. This amount was charged to stockholders’
deficit upon the completion of the IPO.

Concentration of Credit Risk

Financial instruments that
potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times,
may exceed the